LENTIVIRAL AIRWAY GENE TRANSFER IN NORMAL FERRETS

Patricia Cmielewski[1,4], Nigel Farrow[1,4], Chantelle McIntyre[1,4], Harsha Padmanabhan[1,4], Martin Donnelley[1,4], Tim Rucher[1,4] & David Parsons[1,4,5]

1. Respiratory and Sleep Medicine, Women's and Children's Hospital, South Australia
2. Women's and Children's Health Research Institute, South Australia
3. School of Paediatrics and Reproductive Health
4. Robinson Research Institute, and the Centre for Stem Cell Research, University of Adelaide
5. Pre-clinical Imaging and Research Laboratories , South Australian Health and Medical Research Institute, Adelaide

BACKGROUND: With the recent availability of the cystic fibrosis (CF) ferret model, we wished to assess the ability of our HIV-1 based Lentiviral (LV) vector to produce gene transfer in ferret airways.

Our airway gene delivery protocol employs a lysophosphatidylcholine (LPC) pre-treatment, which enables robust expression in marmoset lung, and long lasting gene expression in mouse nasal airways.
This pilot study asked whether this protocol was effective in normal ferret lung airway, prior to consideration of studies in CF ferrets.

METHODS: Six recently-weaned ferrets (2 M, 4 F, 335 to 382 gram bwt at 7 weeks of age) were anaesthetised and orally intubated. Our HIV-1 based LV vector containing a nuclear-localised LacZ gene (500 µL x 5 x 10^8 TU/mL) was delivered 1 hour [illegible]. Blood vector were delivered via a PE cannula projecting 2 mm from the ET tube into the lower ¼ of the trachea. Blood was taken at baseline and on alternate days. One week later animals were humanely killed (Lethabarb i.p.). upper right lobe was removed prior to inflation fixation for molecular biology analyses, along with other non-airway tissues, and the trachea and lung tissues were inflation-fixated and processed to reveal LacZ protein expression (standard X-Gal procedures). The airway tissues were first examined *en face* to identify transduced regions. Subsequently, selected regions of transduced tissue were sectioned and counter-stained to identify transduced cells.

RESULTS: Clear but low-level LacZ gene expression was present in the 6 ferrets, evident primarily as blue-stained cells in the trachea (below).

Low levels of LacZ transduction in the trachea of the 6 ferrets studied. *En face* view. x20 magnification except lower left is x30



(Above) Together with clusters of ciliated and non-ciliated cells (fine arrows) and basal cells (thick arrow on low power section) were transduced in the tracheal epithelium.

In the lung only rare macrophages (arrow) were detected in one or two, in some animals (right). Scale bar 10

Vector presence in serum was sought via p24 assay; p24 was not detected above baseline levels on any day (pre, 1, 3, 5 & 7 days) in any animal.

Using qPCR analysis of lung, spleen, liver, gonads harvested at day 7 the LacZ gene was not detected in these tissues in any animal.

CONCLUSION:
Our combined LPC/LV delivery protocol can produce airway gene transfer in normal ferret lung airways. Compared to the strong and extensive LacZ gene expression we have reported in airways of mice and marmosets, the extent and efficiency of gene expression was (qualitatively) low and did not warrant quantitation.
Factors influencing this reduced LacZ gene expression may be LV vector spreading and dilution after delivery within the very long trachea; a sub-optimal LPC pre-treatment dose provided by single 150 µl volume use, and it is possible that setting a vector dose volume by scaling on body weight is not appropriate. In the lung the rarity of alveolar macrophages is consistent with an inadequate dose volume. The absence of both vector p24 protein and LacZ transgene in blood and harvested organs, respectively, could also be due to an inadequate vector dose. Alternatively there may be species-related factors that reduce transduction efficiency in ferret lung compared to [illegible] models. Future dose-response studies would be informative.
[illegible] airway gene therapy. These findings supporting the utility of our airway gene transfer method by extending it to another animal species.

ACKNOWLEDGEMENTS:
Supported by NHMRC Australia, the Cure4CF Foundation, and the Allan Scott family administered by the WCH Foundation. We thank Loren Matthews, Kevin Neumann and Daniel Johns at PIRL for husbandry and technical assistance.